相关实验视频

Updated: Jan 18, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

治疗前循环血管生物标志物预测癌症治疗相关的心脏功能障碍在 HER2 乳腺癌治疗期间

Dakota Gustafson¹, Priya Mistry¹, Crizza Ching²

¹Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

JACC. CardioOncology

|January 17, 2026

概括

在HER2阳性乳腺癌患者中预测癌症治疗相关心脏功能障碍 (CTRCD) 风险至关重要. 治疗前的内皮和炎症生物标志物在化学疗法期间识别高风险CTRCD患者方面表现有前途.

科学领域:

心脏病学和瘤学
生物标志物发现发现
精准医学是一门精准的医学.

背景情况:

血液生物标志物的有限可用性,以预测与癌症治疗相关的心脏功能障碍 (CTRCD).
在接受心脏毒性治疗的HER2阳性乳腺癌患者中需要预测标志物.

研究的目的:

确定循环生物标志物,以预测HER2阳性乳腺癌患者中CTRCD风险.
评估内皮细胞激活,炎症和microRNA资料,用于CTRCD预测.

主要方法:

在接受 antracycline 和 trastuzumab 的患者中,对生物标记物 (蛋白质,微RNA) 的多组学分析.
使用心脏磁共振成像 (CMR) 和心声回声学进行连续心脏评估.
在独立的队列中验证预处理生物标志物.

主要成果:

治疗前炎症标志物 (髓氧化酶,干扰素诱导蛋白-10) 和内皮标志物 (angiopoietin-2,内皮蛋白) 的升高与CTRCD的发展有关.
在患有CTRCD的患者中发现了明显的microRNA签名.
整合生物标志物的预测模型超过了临床和CMR措施.

结论:

预处理内皮细胞中心和炎症生物标志物在预测CTRCD方面优于临床和CMR措施.
这些生物标志物为HER2阳性乳腺癌患者早期风险分层提供了有希望的方法.

关键词:

血管蛋白-2,生物标志物乳腺癌乳腺癌乳腺癌癌症治疗相关的心脏功能障碍心脏瘤学心脏瘤学它们的内皮质 (endothelium).这是一种炎症炎症炎症炎症.机器学习是机器学习.这是一个微型RNA.骨髓氧化酶是如何形成的血管血管血管血管

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

相关概念视频

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...